https://media.gm.com/media/us/en/gm/news.detail.html/content/Pages/news/us/en/2021/jul/0715-ultium.html
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program; Clinical Trial to Enroll Patients with Early-stage Multiple Systems Atrophy
Alterity Therapeutics (NASDAQ: ATHE) ("Alterity" or "the Company") today announced an expansion of the clinical development program for the Company's lead asset, ATH434, in patients with Multiple System Atrophy (MSA), a rare and rapidly progressing Parkinsonian disorder.
